Real-world clinical experience with long-term albumin therapy in advanced liver disease: a case-based perspective and expert opinion from Asia
Translational Gastroenterology and Hepatology · 2023-01 · 0-0
DOI: 10.21037/tgh-2026-0132 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Gastroenterology and Hepatology, 2023-01. Verfasst von Anand V. Kulkarni und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Long-term albumin (LTA) therapy is a potential disease-modifying strategy for advanced liver disease. Randomized trials and real-world studies suggest that LTA improved survival and reduced liver-related complications. LTA use in Asia remains heterogeneous reflecting disparities in patient characteristics, healthcare systems, and treatment access. This study evaluated clinical rationale, therapeutic strategies, and outcomes of LTA in advanced liver disease across five tertiary centers in Asia. An expert panel was convened to discuss the cases, current practices and consensus development of LTA recommendations.
Methods
Eight cases from Indonesia, India, and Malaysia, with decompensated cirrhosis who received LTA for ≥3 months were discussed. Each case was analyzed for therapeutic rationale, safety, and outcomes. Panelists completed pre-meeting survey, followed by structured in-person discussion.
Results
Patients had varied etiologies of cirrhosis, complications, and baseline serum albumin levels generally below 3.0 g/dL, except one hepatitis B virus (HBV)-related cirrhosis with 3.1 g/dL. LTA regimen ranged from fixed dosing (60 g/week loading followed by 20–40 g/week maintenance) to individualized titration based on clinical response and serum albumin level; one patient with HBV-cirrhosis received 25 g/month with clinical benefit. LTA increased serum albumin, reduced paracentesis frequency, and improved renal function in selected case. Reductions in ascites burden or paracentesis requirement were reported in several patients, whereas one patient with polycystic liver disease continued to require twice-weekly paracentesis. Quality-of-life scores improved during follow-up in two patients with concomitant metastatic hepatocellular carcinoma (HCC). One patient experienced two episodes of post-infusion dyspnea suggestive of transient fluid overload following rapid albumin administration.
Conclusions
This study provides real-world insights into patient selection, dosing strategies, and observed clinical courses and outcomes of LTA use in routine clinical practice. Given the small sample size and descriptive nature of the study, the findings should be interpreted cautiously and are hypothesis-generating rather than confirmatory. Further prospective studies and real-world evaluations are needed to better define the role of LTA in Asian population.
Zitieren
APA
Kulkarni, A. V., Gyanwali, B., Lesmana, C. R. A., Kalista, K. F., Mohamed, R., Tan, S., & Chan, W. K. (2023). Real-world clinical experience with long-term albumin therapy in advanced liver disease: a case-based perspective and expert opinion from Asia. Translational Gastroenterology and Hepatology, 0, 0-0. https://doi.org/10.21037/tgh-2026-0132
Vancouver
Kulkarni AV, Gyanwali B, Lesmana CRA, Kalista KF, Mohamed R, Tan S, et al. Real-world clinical experience with long-term albumin therapy in advanced liver disease: a case-based perspective and expert opinion from Asia. Translational Gastroenterology and Hepatology. 2023;0:0-0. doi:10.21037/tgh-2026-0132
BibTeX
@article{Kulkarni2023,
author = {Kulkarni, Anand V. and Gyanwali, Bibek and Lesmana, Cosmas Rinaldi A. and Kalista, Kemal Fariz and Mohamed, Rosmawati and Tan, Soek-Siam and Chan, Wah Kheong},
title = {Real-world clinical experience with long-term albumin therapy in advanced liver disease: a case-based perspective and expert opinion from Asia},
journal = {Translational Gastroenterology and Hepatology},
year = {2023},
volume = {0},
pages = {0--0},
doi = {10.21037/tgh-2026-0132}
}
EUVIMED